. Overview of calibration data for the thirteen runs carried out for quantification of insulin-like growth factor 1 (IGF1) in the clinical samples. The scatter plot features individual data points for all calibrants which were measured during the thirteen analytical runs carried out for clinical sample analysis, and which furthermore met the criteria as stipulated in the United States Food and Drug Administration guidelines on bioanalytical method validation [1]. Coefficients of determination for the thirteen analytical runs were between 0.9977 and 0.9996 based on a 1/xweighted quadratic regression model. A linear regression curve plus corresponding statistics is included for the linear regression analysis based on the average IGF1 levels of the calibrants.
. Overview of the quality control data obtained during the thirteen runs carried out for quantification of insulin-like growth factor 1 (IGF1) in the clinical samples. Quality Control (QC) samples with levels around 3-4 times the lower limit of quantification (QC-low), with midrange levels (QC-medium), and with levels around 70% of the upper limit of quantification (QC-high) were processed in duplicate during each analytical run. As is shown in the figure, biases within ± 15% were observed for a sufficient number of QC samples in order to meet the regulatory requirements [1] which specify that at least 4 out of 6 of the QC samples (and at least one of the two samples at the same QC level) should be within ± 15% of their respective nominal value. 
